Bull
$10.01
シナリオ価格
$20.740
-0.732 (-3.53%)終値時点
Phoenix Asia Holdings Ltd is an investment holding company mainly engaged in the substructure works business. The Company is mainly engaged in site formation, ground investigation and foundation works business as subcontractor. The Company also provides other construction services such as structural steelworks, advisory services and supervision services in substructure projects.
Phoenix Asia Holdings Ltd (PHOE) is currently trading at $20.74, which is a significant drop of 7.25% over the last five days. The RSI is at 41.939, indicating that the stock is nearing oversold territory. However, the forward P/E ratio is currently at 0, suggesting that earnings expectations are uncertain. The recent acquisition of ACEA Therapeutics for $1 billion has driven a surge in optimism, with shares previously rising 169%. The main risk is the recent 5-day decline of 7.25%, which could indicate volatility in the short term.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

ACEA Therapeutics to be Acquired by Phoenix Asia in $1 Billion Deal

Scilex Acquires ACEA Pharma for $1 Billion

SCILEX HOLDING CO - ACEA THERA TO ACQUIRE APPROXIMATELY 82% OF THE CONTINUING COMPANY AFTER CLOSURE

SCILEX HOLDING CO - PHOENIX TO CHANGE NAME TO ACEA PHARMA, INC. AND PLANS TO DEBUT ON NASDAQ

SCILEX HOLDING CO - ACEA THERA TO DIVEST ENTIRE STAKE IN ACEA PHARMA TO PHOENIX FOR $1 BILLION IN STOCK
Phoenix Asia Holdings Ltd is an investment holding company mainly engaged in the substructure works business. The Company is mainly engaged in site formation, ground investigation and foundation works business as subcontractor. The Company also provides other construction services such as structural steelworks, advisory services and supervision services in substructure projects. It operates in the Industrials sector.
Phoenix Asia Holdings Ltd (PHOE) is currently trading at $20.74, which is a significant drop of 7.25% over the last five days. The RSI is at 41.939, indicating that the stock is nearing oversold territory. However, the forward P/E ratio is currently at 0, suggesting that earnings expectations are uncertain. The recent acquisition of ACEA Therapeutics for $1 billion has driven a surge in optimism, with shares previously rising 169%. The main risk is the recent 5-day decline of 7.25%, which could indicate volatility in the short term.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。